(Total Views: 749)
Posted On: 03/30/2022 7:12:02 PM
Post# of 145247
Could it also be we put a hold on production with Samsung and therefore the manufacturing part of the bla is not active? We already submitted the non clinical which I believe is the safety data so there should not be problems there. I would guess any data discrepancy would have appeared then. Could it be a extension patient past away and the fda wants to know if it was related to leronlimab and until they do the temporary hold is in place?
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)